Pfizer to acquire GSK meningitis vaccines
22 June 2015 | By Victoria White
Pfizer has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for $130 million...
List view / Grid view
News
New analysis from Phase 3 trial of Adcetris in Hodgkin’s lymphoma patients presented at ICML 2015
22 June 2015 | By Victoria White
Results from a new sub-analysis of the Phase 3 Aethera clinical trial of Adcetris were presented at the 13th International Conference on Malignant Lymphoma...
Epizyme releases additional data from Phase 1 study of tazemetostat in non-Hodgkin’s lymphoma
22 June 2015 | By Victoria White
Epizyme has reported results from the ongoing Phase 1 trial of tazemetostat in patients with advanced B-cell non-Hodgkin's lymphoma and solid tumours...
EC approves Opdivo for the treatment of advanced melanoma patients
22 June 2015 | By Victoria White
The European Commission has approved Bristol-Myers Squibb’s Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced melanoma in adults...
CPhI China opens as country invests in R&D
22 June 2015 | By
CPhI China, hosted by UBM EMEA and CCCMHPIE, returns to the Shanghai New International Exhibition Centre, SNIEC, China from 24 to 26 June 2015...
Celsis introduces the all new Celsis Accel™ Rapid Microbial Screening System for midrange test volumes
20 June 2015 | By Celsis International
Celsis’ Accel System for Pharma allows products to be quickly released from micro hold, diminishing manufacturing cycle times and reducing inventory and working capital requirements...
CYRAMZA® (ramucirumab) Hepatocellular Carcinoma data published by The Lancet Oncology
19 June 2015 | By Eli Lilly and Company
Encouraging subgroup findings are basis for new phase III trial...
AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments
19 June 2015 | By AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG has announced the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state...
Bristol-Myers Squibb to present data from the Orencia Phase IIIb AVERT and AMPLE trials
19 June 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb has announced results from new post hoc analyses of the Phase 3b AVERT and AMPLE trials, which included early moderate to severe rheumatoid arthritis (RA) patients with active disease and markers of poor prognosis...
Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients
18 June 2015 | By Victoria White
Galapagos has completed recruitment for the Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205...
Azithromycin proves strikingly effective against drug-resistant superbugs
18 June 2015 | By Victoria White
A new study shows that the antibiotic azithromycin, often prescribed to cure common infections, kills many multidrug-resistant bacteria very effectively...
LY2951742 met the primary endpoint in a Phase 2b study in episodic migraine
18 June 2015 | By Victoria White
Lilly’s investigational medicine for the prevention of migraine, LY2951742, met the primary endpoint in a Phase 2b study in episodic migraine...
NICE seeks more information on idelalisib from Gilead
18 June 2015 | By Victoria White
NICE has opened a consultation on preliminary draft guidance for the drug idelalisib (Zydelig) for adults with chronic lymphocytic leukaemia...
Roche to provide HIV diagnostic solutions to Global Fund
18 June 2015 | By Victoria White
Roche has been selected to provide HIV-1 viral load and early infant diagnostic technologies for the Global Fund...
New mandatory logo for selling medicines online
18 June 2015 | By Victoria White
From 1 July, anyone in the UK selling medicines online needs to be registered with the MHRA and to be on the MHRA’s list of registered online retail sellers...
